
    
      A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase 3 Safety and Effectiveness
      Trial of a Vaginal Matrix Ring Containing Dapivirine for the Prevention of HIV-1 Infection in
      Women." MTN-020 will enroll approximately 3676 sexually active HIVnegative women aged 18-45
      years randomized in a 1:1 ratio to receive either a vaginal ring containing 25 mg of
      dapivirine or a placebo vaginal ring. Rings will be inserted once every 28 days for 12
      consecutive months. MTN expects to initiate this study in August 2012.
    
  